Biomedical Engineering Reference
In-Depth Information
102. Waddell, D.D.,
The tolerability of viscosupplementation: low incidence
and clinical management of local adverse events.
Curr Med Res Opin,
2003.
19
(7): p. 575-580.
103. Bellamy, N., et al.,
Viscosupplementation for the treatment of
osteoarthritis of the knee.
Cochrane Database Syst Rev, 2006(2): p.
CD005321.
104. Bhardwaj, R. and M.C. Parker,
Impact of adhesions in colorectal surgery.
Colorectal Dis, 2007.
9 Suppl 2
: p. 45-53.
105. Boland, G.M. and R.J. Weigel,
Formation and prevention of postoperative
abdominal adhesions.
J Surg Res, 2006.
132
(1): p. 3-12.
106. Zeng, Q., et al.,
Efficacy and safety of Seprafilm for preventing
postoperative abdominal adhesion: systematic review and meta-analysis.
World J Surg, 2007.
31
(11): p. 2125-2131; discussion 2132.
107. Vasey, P.A., et al., Phase I clinical and pharmacokinetic study of PK1
[
N
-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First
member of a new class of chemotherapeutic agents — Drug-polymer
conjugates
.
Clin Cancer Res, 1999.
5
(1): p. 83-94.
108. Seymour, L.W., et al.,
Hepatic drug targeting: phase I evaluation of
polymer-bound doxorubicin.
J Clin Oncol, 2002.
20
(6): p. 1668-1676.
109. Seymour, L.W., et al.,
Phase II studies of polymer-doxorubicin (PK1,
FCE28068) in the treatment of breast, lung and colorectal cancer.
Int J
Oncol, 2009.
34
(6): p. 1629-1636.
110. Vercauteren, R., E. Schacht, and R. Duncan,
Effect of the Chemical
Modification of Dextran on the Degradation by Rat Liver Lysosomal
Enzymes.
J Bioactive Compatible Polym, 1992.
7
(4): p. 346-357.
111. Auzenne, E., et al.,
Superior therapeutic profile of poly-L-glutamic acid-
paclitaxel copolymer compared with taxol in xenogeneic compartmental
models of human ovarian carcinoma.
Clin Cancer Res, 2002.
8
(2): p.
573-581.
112.
http://www.celltherapeutics.com/pdf/OPAXIO_facts-4pg.pdf
.
113. Paz-Ares, L., et al.,
Phase III trial comparing paclitaxel poliglumex vs
docetaxel in the second-line treatment of non-small-cell lung cancer.
Br J
Cancer, 2008.
98
(10): p. 1608-1613.
114. O'Brien, M.E., et al.,
Randomized phase III trial comparing single-agent
paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or
vinorelbine for the treatment of PS 2 patients with chemotherapy-naive
advanced non-small cell lung cancer.
J Thorac Oncol, 2008.
3
(7): p.
728-734.
115. Langer, C.J., et al.,
Phase III trial comparing paclitaxel poliglumex (CT-
2103, PPX) in combination with carboplatin versus standard paclitaxel
Search WWH ::
Custom Search